Top

Published in:

01-04-2016 | Brief Report

MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer

Authors: Young-Ae Kim, Hee Jin Lee, Sun-Hee Heo, Hye Seon Park, Suk Young Park, WonSeon Bang, In Hye Song, In Ah Park, Gyungyub Gong

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Abstract

Interferons (IFNs) play an important role in tumor–immune system interactions. As one of the main mediators of IFNs, myxovirus resistance A (MxA) is upregulated in various cancers. However, the exact role of MxA in breast cancer is not fully understood. As part of the immune response to tumors, tumor-infiltrating lymphocytes (TILs) have prognostic significance in breast cancer. The aim of our present study was to examine the relationship between MxA and immune system components, including the amount of TILs and human leukocyte antigen (HLA) expression, in breast cancer. TILs, MxA expression, HLA intensity, and clinicopathological factors were retrospectively analyzed in 688 patients with primary breast cancer between 1993 and 1998 and in 705 patients with triple-negative breast cancer (TNBC) between 2004 and 2011. MxA expression was higher in TNBC tumors than in other subtypes. High MxA levels were associated with a higher histologic grade, abundant TILs, and stronger HLA-ABC expression in both the TNBC subtype within the consecutive breast cancer cohort and the validation TNBC cohort. MxA expression showed a significant positive correlation with TILs, the number of CD8⁺ cells, and the number of CD69⁺ cells in the validation TNBC cohort. High MxA levels and abundant TILs were found to be independent prognostic factors for disease-free survival in patients with TNBC. These results indicate that MxA expression is closely related to TILs in TNBC and, along with TILs, provides prognostic information after chemotherapy in patients with TNBC.

Available only for authorised users

McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 133:66–76CrossRefPubMed

Perez-Balaguer A, Ortiz-Martinez F, Garcia-Martinez A, Pomares-Navarro C, Lerma E, Peiro G (2015) FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma. Breast Cancer Res Treat 153(2):465–474CrossRefPubMed

Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y et al (2015) Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. Breast Cancer Res Treat 150(3):487–499CrossRefPubMedPubMedCentral

van Rooijen JM, Stutvoet TS, Schroder CP, de Vries EG (2015) Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacol Ther 156:90–101CrossRefPubMed

Hu X, Stern HM, Ge L, O’Brien C, Haydu L, Honchell CD, Haverty PM et al (2009) Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7(4):511–522CrossRefPubMed

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399PubMed

Disis ML, Stanton SE (2015) Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book 35:e25–e30CrossRef

Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM (2015) Therapies for triple negative breast cancer. Expert Opin Pharmacother 16(7):983–998CrossRefPubMed

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7):860–867CrossRefPubMed

10.

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966CrossRefPubMedPubMedCentral

11.

Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113CrossRefPubMed

12.

Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G (2013) Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 16(1):32–39CrossRefPubMedPubMedCentral

13.

Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J (2015) Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res 17:6CrossRefPubMedPubMedCentral

14.

Liu YP, Suksanpaisan L, Steele MB, Russell SJ, Peng KW (2013) Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci Rep 3:2375PubMedPubMedCentral

15.

Callari M, Musella V, Di Buduo E, Sensi M, Miodini P, Dugo M, Orlandi R et al (2014) Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. Mol Oncol 8(7):1278–1289CrossRefPubMed

16.

Hu JL, Hua YJ, Chen Y, Yu B, Gao S (2015) Structural analysis of tumor-related single amino acid mutations in human MxA protein. Chin J Cancer 34(3):55CrossRefPubMedCentral

17.

Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, Gong G (2015) Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol. doi:10.1136/jclinpath-2015-203089 PubMedCentral

18.

Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, Gong G (2015) Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant Trastuzumab. Am J Clin Pathol 144(2):278–288CrossRefPubMed

19.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072CrossRefPubMed

20.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271CrossRefPubMed

21.

Lakhani SREI, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon

22.

Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, Ahn JH et al (2014) Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol 21(5):1561–1568CrossRefPubMed

23.

Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6(4):195–197CrossRefPubMedPubMedCentral

24.

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481PubMed

25.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC et al (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256CrossRefPubMedPubMedCentral

26.

Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T et al (2012) Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 62(5):303–308CrossRefPubMed

27.

Haller O, Staeheli P, Schwemmle M, Kochs G (2015) Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 23(3):154–163CrossRefPubMed

28.

Welsh RM, Bahl K, Marshall HD, Urban SL (2012) Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog 8(1):e1002352CrossRefPubMedPubMedCentral

29.

Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F et al (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103(6):759–767CrossRefPubMed

30.

Lindahl P, Gresser I, Leary P, Tovey M (1976) Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci USA 73(4):1284–1287CrossRefPubMedPubMedCentral

31.

Ismail A, Yusuf N (2014) Type I interferons: key players in normal skin and select cutaneous malignancies. Dermatol Res Pract 2014:847545PubMedPubMedCentral

32.

Tsavaris N, Baxevanis C, Kosmidis P, Papamichael M (1996) The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. Cancer Immunol Immunother 43(2):94–102CrossRefPubMed

33.

Chaganty BKR, Lu Y, Somanchi SS, Lee DA, Fan Z (2015) Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFN-γ secretion. Oncoimmunology. doi:10.1080/2162402X.2015.1100790

34.

Zhang H, Angelopoulos N, Xu Y, Grothey A, Nunes J, Stebbing J, Giamas G (2015) Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. Breast Cancer Res Treat 151(3):555–568CrossRefPubMedPubMedCentral

35.

Liikanen I, Monsurro V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S et al (2011) Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 19(10):1858–1866CrossRefPubMedPubMedCentral

36.

Lee SH, Vidal SM (2002) Functional diversity of Mx proteins: variations on a theme of host resistance to infection. Genome Res 12(4):527–530CrossRefPubMed

37.

Croner RS, Sturzl M, Rau TT, Metodieva G, Geppert CI, Naschberger E, Lausen B et al (2014) Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis. Int J Cancer 135(12):2878–2886CrossRefPubMedPubMedCentral

38.

Brown SG, Knowell AE, Hunt A, Patel D, Bhosle S, Chaudhary J (2015) Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate 75(3):266–279CrossRefPubMedPubMedCentral

39.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20(11):1301–1309CrossRefPubMed

40.

Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T et al (2012) Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One 7(1):e29653CrossRefPubMedPubMedCentral

Title: MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer
Authors: Young-Ae Kim
Hee Jin Lee
Sun-Hee Heo
Hye Seon Park
Suk Young Park
WonSeon Bang
In Hye Song
In Ah Park
Gyungyub Gong
Publication date: 01-04-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3786-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Erratum to: FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells

Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

Peri-operative biology in primary breast cancer: a credible therapeutic target

Prognostic factors in male breast cancer: a population-based study

High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer